Bottom line
XPH vs PHPIX: the short answer
XPH (State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF) and PHPIX (Pharmaceuticals Ultrasector Profund) share a meaningful slice of their top holdings — about 44% by weight.
XPH is cheaper at 0.35% vs 1.78% — a difference of $143 a year per $10,000 invested.
Over five years, XPH returned +2.8% a year vs +1.6% for PHPIX (reporting dates differ).
Updated Nov 19, 2026
XPH vs PHPIX side by side
| XPH | PHPIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | ProShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.35% | 1.78% |
| Annual cost per $10k | $35 | $178 |
| 10-yr cost on $10k (prospectus) | $443 | $2,809 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +31.6% | +1.4% |
| 5-yr return (annualized) | +2.8% | +1.6% |
| 10-yr return (annualized) | +1.9% | +2.4% |
| Best quarter | +28.6% | +22.2% |
| Worst quarter | −24.3% | −24.2% |
| Net assets (fund) | $428.4M | $8.6M |
| Number of holdings | 67 | 74 |
| Portfolio turnover | 69% | 178% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XPH | PHPIX | Difference |
|---|---|---|---|
| 2024 | +5.1% | +1.4% | +3.8% |
| 2023 | +2.9% | −11.3% | +14.1% |
| 2022 | −9.8% | −10.7% | +1.0% |
| 2021 | −10.5% | +17.0% | −27.5% |
| 2020 | +14.4% | +15.5% | −1.1% |
| 2019 | +25.7% | +20.0% | +5.7% |
| 2018 | −15.2% | −14.9% | −0.3% |
| 2017 | +12.0% | +15.0% | −3.0% |
| 2016 | −23.2% | −6.3% | −16.9% |
| 2015 | +1.5% | +5.8% | −4.3% |
Source: Fund prospectus bar charts
Holdings overlap
17 of XPH's top 25 holdings also appear in PHPIX's top 25.
| Holding | XPH | PHPIX |
|---|---|---|
| Definium Therapeutics Inc | 3.09% | 2.00% |
| MBX Biosciences Inc | 2.72% | 2.28% |
| Alumis Inc | 2.14% | 1.51% |
| AtaiBeckley Inc | 2.13% | 2.03% |
| Trevi Therapeutics Inc | 2.12% | 1.46% |
| Enliven Therapeutics Inc | 2.09% | 1.59% |
| Amylyx Pharmaceuticals Inc | 2.04% | 1.62% |
| VeraDermics Inc | 2.02% | 1.21% |
| Ligand Pharmaceuticals Inc | 1.94% | 1.24% |
| Nuvation Bio Inc | 1.89% | 1.48% |
| Edgewise Therapeutics Inc | 1.88% | 1.25% |
| Nektar Therapeutics | 1.88% | 1.33% |
| Liquidia Corp | 1.86% | 1.38% |
| Amneal Pharmaceuticals Inc | 1.72% | 1.28% |
| Corcept Therapeutics Inc | 1.70% | 1.57% |
Source: SEC Form N-PORT
XPH top 10
- State Street Global Advisors — 8.58%
- Definium Therapeutics Inc — 3.09%
- MBX Biosciences Inc — 2.72%
- Alumis Inc — 2.14%
- AtaiBeckley Inc — 2.13%
- Trevi Therapeutics Inc — 2.12%
- Enliven Therapeutics Inc — 2.09%
- Amylyx Pharmaceuticals Inc — 2.04%
- VeraDermics Inc — 2.02%
- Ligand Pharmaceuticals Inc — 1.94%
PHPIX top 10
- N/a — 8.20%
- N/a — 6.31%
- N/a — 5.05%
- N/a — 5.05%
- N/a — 3.95%
- Crinetics Pharmaceuticals Inc — 2.60%
- Mbx Biosciences Inc — 2.28%
- Ataibeckley Inc — 2.03%
- Definium Therapeutics Inc — 2.00%
- Amylyx Pharmaceuticals Inc — 1.62%
FAQ
What is the difference between XPH and PHPIX?
Which is cheaper, XPH or PHPIX?
Should I own both XPH and PHPIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.